Overview

PR104 and G-CSF in Treating Patients With Solid Tumors

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving PR-104 together with G-CSF may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 when given together with G-CSF in treating patients with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Proacta, Incorporated
Treatments:
Lenograstim
Misonidazole